An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer.

Trial Profile

An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2015

At a glance

  • Drugs Carboplatin; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 09 Jun 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top